Boards of Directors

Global Executive Board of Directors

Giles Platford, Takeda - Chair
David Bell, Grifols
Paolo Marcucci, Kedrion SpA
Bio Products Laboratory
CSL Behring

EU Board of Directors

Ainhoa Mendizabal Zubiaga, Grifols - Chair
Richard Corliss, Takeda
Tim Leijten, Prothya Biosolutions
Michael Mensa, Bio Products Laboratory
Oliver Schmitt, CSL Behring
Roberto Tana, Kedrion

N.A. Board of Directors

Bill Zabel, Grifols - Chair
Giorgio Masetti-Zannini, Kedrion Biopharma, Inc.
Adam Grossman, ADMA Biologics, Inc.
Chris Shane, CSL Behring
Brandon Monk, Takeda
Bob Rossilli, Bio Products Laboratory

Global Plasma Board of Directors

Peter Allen, Grifols Plasma Operations - Chair
Roger Brinser, Takeda/BioLife
Allen Coleman, CSL Plasma
Scott Frerichs, BPL Plasma
Milan Maly, UNICAplasma s.r.o.
Rudolf Meixner, PlasmaVita Healthcare GmbH
Paolo Melloni, Kedrion
David Morad, Southern Blood Services
Jerome Parnell III, Immunotek Bio Centers
Cyndi Tolman, ADMA Biologics

PPTA News

PPTA Statement on the draft EU Substances of Human Origin Regulation +

PPTA welcomes positive developments but regrets missed opportunities to support plasma donors and patients who rely on plasma-derived medicinal products (PDMPs)

Brussels, Belgium (July 14, 2022). While the text of the draft regulation on Substances of Human Origin (SoHo) addresses a number of PPTA’s concerns, it has missed the opportunity to help Member States increase plasma collection to improve the reliable availability of life-saving, plasma-derived therapies to patients with a wide range of rare and complex, chronic diseases. As much as 38% of the plasma used to produce medicines for the EU’s 300,000 rare disease patients who rely on PDMPs comes from the U.S., a reliance highlighted during the pandemic, when critical plasma donations declined significantly.
Read More
Monkeypox Virus and Plasma Protein Therapies +

PPTA considers that the current MPXV outbreak is not a concern for the safety margins of plasma protein therapies manufactured by PPTA member companies. This assessment is also shared by other concerned parties (AABB, WHO).

Since May 2022, Monkeypox virus (MPXV) infections have been reported in non-endemic countries across Europe and North America (WHO, CDC, ECDC). People who use plasma protein therapies are understandably concerned about whether their therapies remain safe, with respect to MPXV. To address this issue, PPTA has summarized currently available facts.
Read More
Announcing PPTA’s New Global Chair +

It is with great pleasure that the Plasma Protein Therapeutics Association (PPTA) announces the election of Giles Platford from Takeda to the Chair of the PPTA Global Board.
Read More
PPTA's 2021 Annual Report Now Available +

On March 16, PPTA published its 2021 Annual Report, providing an overview of the Association’s activities throughout the year. This year’s digital report offers readers an engaging and interactive experience as they read about PPTA’s work on behalf of its global membership and in support of patients who rely on plasma-derived therapies. We invite you to read the report here.
Read More

1
2
3

› ‹

Mission Video

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives.
Find a Donation Center.

The need for plasma and plasma donors is more urgent than ever before. Visit givingplasma.org to learn more and to find a donation center near you.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2022 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap